默克公司 (Merck) 因新药增长势头强劲上调销售预测 (MRK:NYSE)
· seekingalpha.com
默克第二季度盈利超出预期，主要得益于 Keytruda 和 Winrevair 的销售；营收增长 5% 并上调了业绩指引。
Merck (MRK) reported second-quarter results that topped Wall Street expectations, driven by continued strength in its blockbuster cancer drug Keytruda, as well ...